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1.0 Introduction 
 
The progression of the periodontal intrabony lesion, as manifested by damage to 
the connective tissue attachment and bone loss, can eventually lead to tooth loss in the 
absence of an intervention [1].  Decades of research in periodontal regeneration therapy 
have produced various materials and products as well as innovative surgical approaches 
resulting in clinically significant levels of regenerative success for patients.   
One recent regenerative material showing promise is GEM-21 (rhPDGF-BB with 
β-TCP).  In vitro studies, randomized clinical trials, and systematic reviews have 
confirmed its clinical and statistical benefit in treating intrabony defects [2-6].  Progress 
in flap management has moved towards smaller, less traumatic surgical approaches with 
the goal of maximizing the innate healing potential of the periodontium.  The success of 
minimally invasive surgery has been confirmed in systematic reviews and meta-analyses, 
but to what extent one approach may have greater clinical benefit than another needs to 
be further investigated [7, 8]. 
To date, there is only one randomized clinical trial that evaluates minimally 
invasive surgery by directly comparing the single flap approach (SFA) to the double flap 
approach (DFA) [9].  On the contrary, these approaches have been tested extensively in 
the literature both alone or with other treatment adjuncts.  These minimally invasive 
surgical approaches not only have the potential for greater clinical success as measured 
by traditional periodontal parameters, but also may have greater patient-centered 
outcomes in the form of less post-operative pain and analgesic consumption. What is not 
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known is whether a surgical approach like the SFA, which maintains space for clot 
maturation and enhances wound stability, will potentiate the regenerative efficacy of a 
treatment adjunct like rhPDGF-BB with β-TCP for a greater clinical benefit in 
comparison to another surgical approach like the DFA. 
Therefore, the aim of this randomized, controlled, parallel-arm clinical trial was to 
compare the clinical, patient-centered, and radiographic outcomes of a regenerative 
strategy based on the use of rhPDGF-BB + β-TCP in deep intraosseous periodontal 
defects accessed with SFA versus DFA. 
2.0 Background and Significance 
 
2.1 Regenerative Periodontal Therapy 
 
2.1.1 A History of Regenerative Periodontal Therapy 
 
The progression of the periodontal lesion, as manifested by damage to the 
connective tissue attachment and bone loss, was considered irreversible until a series of 
studies proved that regenerative periodontal therapy was possible [10]. Early 
investigators observed in animal studies that new bone could grow in bone defects that 
were enclosed with an artificial device [11, 12]; whereas, Karring and Nyman showed in 
animal models specifically which cells contributed to the regeneration of the 
periodontium [13, 14]. They observed that a new periodontal ligament was only re-
established on the root that had remnants of the periodontal ligament (PDL) preserved 
after scaling and root planing.  The portion of the root without remnants of the PDL 
showed ankylosis and root resorption when in contact with bone and gingival connective 
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tissue. In another animal model, the authors induced periodontitis, scaled and root planed, 
and then submerged the roots for healing. They observed a formation of new connective 
tissue attachment on the previously diseased and root planed root area.  It was concluded 
that new attachment is formed by coronal migration of cells originating from the 
periodontal ligament and not from the cells of the bone or gingival connective tissue [15].  
In a human study, they used an occlusive barrier membrane with the purpose of 
excluding epithelium to allow PDL cells to populate the root and form new attachment.  
This study confirmed that use of this barrier membrane led to periodontal regeneration of 
a previously diseased root [16].   
As these experiments were being conducted, Gore-Tex™ began testing the 
clinical application of its expanded polytetrafluoroethylene (ePTFE) occlusive membrane 
for treating periodontal defects.  The clinical success of the ePTFE occlusive membrane 
was shown by histological evidence of periodontal regeneration in both intrabony defects 
and Class II and III furcation defects [17, 18], and by a randomized clinical trial using 
this membrane on Class II furcations showing 90% of the defects with complete 
resolution [19].  This occlusive barrier membrane with the purpose of excluding 
epithelium to allow PDL cells to populate the root and form new attachment seemed to 
explain the clinical success.  
As the clinical success of Guided Tissue Regeneration (GTR) using e-PTFE 
membrane mounted, a group of researchers investigated the use of adding an osseous 
graft to the GTR protocol.  Clinical studies displayed the added benefit of allografts for 
periodontal regeneration, in particular, a five year report showed a superior result of GTR 
with root conditioning and allograft in comparison to GTR alone [20-23].    
 4 
Along with studies showing successful regenerative therapy, a group of reports 
focused on a notable level of GTR failure.  An acknowledged reason for GTR failure was 
flap management resulting in membrane exposure and bacterial infection, but the level of 
failure was variable [24-29].   These reports fueled innovative research to develop new 
regenerative materials including resorbable membranes [30-32] and biologics, and 
surgical approaches such as papilla preservation flaps, minimally invasive surgery, and 
the single flap approach [33-35].   
Decades of research in periodontal regeneration have produced various materials 
and products as well as innovative surgical approaches resulting in clinically significant 
levels of regenerative success for patients.   
2.2 Wound Healing in Periodontal Regeneration 
 
2.2.1 Biologic Factors for Periodontal Regeneration 
 
2.2.1.1 Space Provision 
 
 In evaluating the proven success of guided tissue regeneration, the importance of 
space provision was tested by Wikesjö and coworkers.  For years, the concept of tissue 
occlusion was used to explain GTR success, but in a study where a macroporous ePTFE 
membrane was compared to an occlusive ePTFE membrane it was shown that there was 
no difference in the level of regeneration between the groups [36].  Instead of excluding 
epithelium to allow PDL cells to populate the root and form new attachment, the 
importance of space provision became apparent.  Polimeni et al. treated critical-sized 
defects with either a porous ePTFE membrane adapted according to the GTR protocol or 
no membrane at all [37].  There was a significantly greater level of regeneration when the 
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membrane was used proving that space provision enhanced regeneration.  Moreover, 
Polimeni et al. further studied whether placing a graft with a membrane improved space 
provision and ultimately regeneration [38].  They showed significantly greater 
regeneration when the membrane and graft were used in conjunction.  The authors 
explained that the biomaterial prevented a collapse of the membrane; thus, providing the 
space and support for the blood clot.   
2.2.1.2 Blood clot stabilization 
 
Other factors have been identified as  important for promoting the innate 
regenerative potential of the periodontium.  Early studies observed the importance of a 
stable root surface-adhering blood clot protected from mechanical and microbiological 
insults for regeneration [39-41]. Using the critical-size supraalveolar defect model in 
dogs, the group investigated what happened if the clot was prevented from adhering to 
the root by using heparin [42].  They found that heparin-treated roots had 50% connective 
tissue attachment and the saline-treated roots had 95% connective tissue attachment.  In 
conclusion, manipulation of the clot’s ability to adhere to the root prevented connective 
tissue attachment.  To determine to what extent wound-rupturing forces may have 
disrupted re-attachment, Wikesjö et al. evaluated if placing a graft (polylactic acid) to 
support the clot could neutralize the effects of a heparin-treated root [43]. They found 
that placing a graft to stabilize the blood clot neutralized the effect of heparin on 
connective tissue attachment.  The graft stabilized the wound against disruptive wound-
rupturing forces acting on the gingival margin.  These experiments show the importance 
of a stable blood clot adherent to the root for periodontal regeneration.   
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2.2.1.3 Wound infection 
 
 Unexposed primary intention healing has been shown to be an important factor 
for periodontal regeneration.  An acknowledged reason for GTR failure was flap 
management resulting in membrane exposure and bacterial infection, but the level of 
failure was variable [24-29].  Trombelli et al. did a retrospective analysis to see the effect 
of wound dehiscence on GTR outcome [44].  Exposure versus no exposure was evaluated 
in 38 patients contributing 38 defects, and the average bone gain without exposure was 
4.1 ± 2.3 versus 2.2 ± 2.3 with exposure and this was statistically significant.  Wound 
dehiscence allows for bacterial penetration and provocation of the inflammatory response, 
which worsens the regenerative outcome.   
 There are biologic factors that contribute to creating an optimal environment for 
periodontal regeneration: space provision, stability of the root surface-adhering blood clot, 
and unexposed primary intention healing.  By manipulating these factors, researchers can 
develop regenerative materials to potentiate the innate healing potential of the 
periodontium.  Furthermore, developing a surgical approach that provides maximum 
support and space maintenance for the blood clot, reduces wound-rupturing forces, and 
ensures primary intention healing may enhance the regenerative outcome.  
2.2.2 Innate Regenerative Potential of the Periodontium 
 
 The observation of the innate regenerative potential of the periodontium dates 
back to Björn et al. in 1957 in a dog model and then in humans [45, 46]. In a series of 
studies showing human histology, Bowers et al. showed periodontal regeneration in 
periodontally compromised teeth, which were treated with open flap debridement, with or 
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without demineralized bone matrix, and then submerged [47-50]. This highlighted the 
innate regenerative potential of the periodontium under optimal circumstances.   
 In a recent study in dogs, early periodontal wound healing events were observed 
using histological and immunohistochemical techniques.  The dogs were sacrificed at 2, 5, 
9, and 14 days, and at 4 and 8 weeks [51].  Using the critical-size supraalveolar defect 
model, pro-regeneration and pro-scar-forming domains were identified, which compete 
together to populate the wound space.  The pro-regeneration cells and signals originated 
from the periodontal ligament and bone marrow, while the pro-scar-forming cells and 
signals originated from the gingival tissues.  The net outcome of the competition between 
these two domains modulated by local and systemic factors determined to what extent the 
innate regenerative potential could occur.  The pro-scar-forming domain was dominated 
by fibrous tissue and was separated from the regenerative domain by remnants of the clot.  
These observations indicated that most new tissue formation in the periodontium was 
complete by 14 days in the dog model; thus, making the assumption that in humans, 
regenerated periodontal tissues should be established within 4 weeks.    
2.2.3 Phases of Periodontal Wound Healing 
 
 Wikesjö and coworkers studied the phases of periodontal wound healing [52].  
The immediate response to injury is clot formation.  The clot is protective and also a 
matrix for cell migration as red and white blood cells and platelets move to the site [53, 
54]. The clot functions as a hemostatic plug through its matrix of fibrin and extracellular 
matrix glycoproteins, and plasma proteins begin absorbing and adhering to the root 
surface. In the early stage of inflammation, which is within hours of injury, neutrophils 
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and monocytes cleanse the wound by phagocytosis of bacteria.  In the late phase of 
inflammation, which is within 3 days, macrophages debride the wound through 
phagocytosis, and they also release cytokines and growth factors targeting other cells 
involved in wound repair.  There is also a proliferation and migration of fibroblasts, 
endothelial cells, and smooth muscle cells are seen.  The next phase is the formation of 
granulation tissue occurring at one week.  Granulation tissue begins maturing, and 
myofibroblasts express α-smooth muscle actin, which results in wound contraction.  
Endothelial cells vascularize the site, and a connective tissue attachment may be seen at 
the root surface. The last phase is epithelialization, which begins within hours of injury 
and completes by two weeks.  Whether regeneration or repair occurs depends on the 
availability of the specific cell types and the signals necessary to recruit and stimulate 
these cells.  
By understanding the intricacies of the innate healing potential of the 
periodontium, researchers can develop regenerative materials, which stimulate or amplify, 
specifically, the cells and signals contributing to regeneration.   Moreover, the importance 
of the blood clot adhesion to the root surface for regeneration, emphasizes the need for a 
surgical approach developed to create a favorable environment for clot stabilization.   
2.3 Flap Management 
 
2.3.1 Progress in Flap Management 
 
   An acknowledged reason for GTR failure was flap management resulting in 
membrane exposure and bacterial infection, but the level of failure was variable [24-29].  
In response, clinical innovators began developing new surgical approaches to preserve 
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soft tissue for primary intention healing with the goal of preventing wound dehiscence 
and infection of the regenerative material.    
 Takei et al. proposed in 1985 the Papilla Preservation Technique with the stated 
purpose of achieving primary closure after covering grafted bone defects [55].  The flap 
design began with sulcular incisions, and then was described as a series of semi-lunar 
incisions on the palatal or lingual that started and ended on the straight lingual of the 
involved teeth.  This created a pedicle, which kept the interproximal tissue intact as it was 
passed under the contact point exposing the interproximal osseous defect.  This was a 
double flap approach (DFA) in that both the facial and lingual flaps were elevated. In this 
case series, it was reported that primary intention healing always occurred, and 
interdental soft tissue craters did not develop.   
 Cortellini et al. further modified the double flap approach with the modified 
papilla preservation technique (MPPT) and the simplified papilla preservation flap 
(SPPF) [56, 57].  Cortellini described the purpose of the MPPT was to allow for primary 
closure, but also the coronal positioning of the interdental tissue.  The clinical application 
required an interdental space of greater than 2mm, and the description of the flap design 
began with sulcular incisions around the teeth adjacent to the osseous defect.  A 
horizontal incision was then placed on the buccal at the base of the papilla at the level 
equal to the most apical portion of the buccal gingival margin of the neighboring teeth.  
The interproximal tissue was pushed through the contact point and kept attached to the 
lingual flap.  Vertical incisions were then placed to mobilize the buccal flap coronally for 
primary closure.  Cortellini et al. tested GTR with the MPPT versus a conventional flap 
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in a randomized clinical trial where the clinical attachment level (CAL) gain using the 
MPPT was 5.3 ± 2.2mm versus 4.1 ± 1.9mm for the conventional flap [58].   
 The simplified papilla preservation flap (SPPF) had a similar application as the 
MPPT, but was instead developed for narrow interdental spaces of less than 2mm.  
Cortellini et al. described the flap design as first beginning with an incision that crossed 
the defect-associated papilla [57].  The incision started from the gingival margin at the 
buccal-line angle of the involved tooth, and extended to the mid-interdental portion of the 
papilla under the contact point of the adjacent tooth. Sulcular incisions were placed on 
the buccal and lingual of the teeth adjacent to the defect.  The flaps were elevated with 
the interdental tissue intact and attached to both the buccal and lingual flaps.  Vertical 
incisions and periosteal releasing incisions were placed to mobilized the buccal flap 
coronally for primary closure.  This flap design was preliminarily tested in a case series 
of eighteen intrabony defects in combination with GTR [57].  The average CAL gain 
observed at one year was 4.9 ± 1.8 mm, and in all the cases it was possible to achieve 
primary closure of the flap over the membrane.   
 Harrel and Rees proposed minimally invasive surgery (MIS) with the aim to 
minimize wounds, limit flap reflection, and to gently handle the soft and hard tissues [34].  
Minimally invasive surgery was described as a more precise surgical procedure made 
possible through the use of magnification and microsurgical instruments and materials. 
Harrel described MIS as consisting of an initial sulcular incision around the teeth 
adjacent to the defect, and then joining the sulcular incisions with a single horizontal 
incision placed 2 to 3 mm from the crest of the papilla [59]. Sharp dissection is used to 
elevate the buccal and lingual flaps, and the flap is kept limited to the teeth adjacent to 
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the defect.  The case series reported that MIS had improved clinical parameters, a faster 
rate of healing, less postoperative pain, and improved soft tissue retention of height and 
contour.  In a prospective study where 160 sites were treated with MIS and Emdogain, 
the mean CAL gain was 3.57 mm and the mean change in recession was 0.01 mm [60].   
 Cortellini et al. then published a similar concept, a minimally invasive surgical 
technique, and stressed that this approach maximized wound and blood clot stability and 
primary wound closure for blood clot protection while limiting patient morbidity [61].  
This described a surgical approach that utilized the previously proposed flap designs, 
SPPF and MPPT, but instead, the surgery was done using high-power magnification, the 
mesial-distal extent of the flap was minimized, and no vertical incisions were placed.  If 
possible, only the defect-associated papilla was involved, and only 1-2 mm of the defect-
associated residual bone crest was exposed.  In the two case series published, results 
showed significant improvements with CAL gains of 4.8 ± 1.9 mm and 88.7 ± 20.7% 
resolution of the defect, and there was a great reduction in morbidity [61, 62].   
 The movement towards more minimally invasive flap designs continued with the 
single flap approach (SFA), as first proposed by Trombelli et al. [35, 63],[64].  The SFA 
consists of the elevation of a limited mucoperiosteal flap to allow surgical access from 
either buccal or lingual aspect only leaving the interproximal supracrestal gingival tissues 
intact.  The decision to access from buccal or lingual aspect depends on the position of 
the bone defect.  Maintaining the interproximal supracrestal tissues intact helps facilitate 
flap repositioning and suturing by using the intact papilla to achieve passive primary 
closure. This limits the surgical trauma to the papilla’s vascular supply allowing for faster 
wound healing, greater wound stabilization, and the intact papilla may minimize 
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recession [35, 63, 64]. Sulcular incisions follow the gingival margins of the teeth 
included in the surgical area and the mesio-distal extension of the flap is to be kept 
limited while ensuring access for defect debridement.  An oblique or horizontal, butt-joint 
incision is made at the level of the interdental papilla overlying the intraosseous defect; 
the greater the distance from the tip of the papilla to the underlying bone crest, the more 
apical (i.e. close to the base of the papilla) the buccal incision in the interdental area.  The 
interdental incision is placed at least 1 mm coronal to the underlying bone crest. The SFA 
has been subsequently tested in randomized clinical trials in comparison to the double 
flap approach as well as in conjunction with grafting materials.   
 In 2009, Cortellini et al. proposed a similar flap design to the SFA, which was 
named the modified minimally invasive surgical technique (M-MIST) [65]  The surgical 
approach was described as beginning with either the SPPF or MPPT depending on the 
width of the interdental space.  Then the incision continued intra-sulcular on the buccal to 
the two teeth adjacent to the intraosseous defect and was kept at minimum to allow 
exposure of the coronal edge of the buccal bone crest.  Using a microsurgical blade, the 
interdental granulation tissue is separated from the supracrestal gingival tissues keeping 
the supracrestal gingival tissues attached to the root and continuous with the palatal tissue, 
which was not displaced.  In a case series, the M-MIST was used in 15 patients resulting 
in a 4.5 ± 1.4 mm CAL gain after 1-year in defects 6 ± 1.5mm deep.  Primary closure was 
attained and maintained in all sites, and gingival recession after 1-year increased 0.1 ± 
0.3 mm [65].   
 Progress in flap management began with the goal of properly covering the 
regenerative materials to avoid exposure and bacterial infection.  Years of research 
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showed a shift towards smaller, less traumatic surgical approaches with the intention of 
maximizing the innate healing potential of the periodontium by providing stability for the 
blood clot and wound. Therefore, primary wound closure achieves blood clot protection 
and patient comfort.    
2.3.2 Biologic Advantage of the Single Flap Approach (SFA) 
 
 There are several biologic advantages in using a minimally invasive flap design 
like the single flap approach.  By maintaining the interdental, supracrestal, gingival tissue 
intact, it facilitates flap repositioning and suturing by utilizing the undetached papilla as 
anchorage; thus, optimizing wound closure for primary intention healing [35, 63, 64, 66, 
67].  By achieving primary wound closure, a faster wound healing process occurs 
particularly at the level of the incision line [66].  The wound stabilization and avoidance 
of secondary intention healing along with the preservation of an intact interdental papilla 
may minimize post-surgery recession [64, 65, 68].  Moreover, limiting the surgical 
trauma on the papilla diminishes the vascular impairment that occurs as a result of trauma, 
which may partly explain the favorable CAL gain and minimal recession seen with the 
SFA [69-73].   
2.3.3 Systematic Reviews and Meta-analyses for Flap Designs 
 
 Tu et al. in a meta-analysis of randomized-controlled trials evaluated if there is a 
temporal trend in the reported treatment efficacy of periodontal regeneration [8]. By 
evaluating probing depth and CAL gain over time, a comparison between GTR and 
Enamel  Matrix Derivatives (EMD)  groups versus their Open Flap Debridement (OFD) 
controls showed improvement from 1998 to 2006, and the OFD controls had the same or 
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a slightly better rate of improvement.  The authors attributed the improvement over time 
in both test and control groups to greater experience and improved surgical technique.   
 In a more recent systematic review, Graziani et al. analyzed the clinical 
performance of access flap surgery in the treatment of the intrabony defect [7].  
Conservative surgeries were included in the meta-analysis, and they were defined as 
surgical procedures aimed at gaining access to the root surface with no active removal of 
bone and most often no resection of soft tissues.  Flap designs were categorized from 
least to most conservative approaches.  The least conservative group consisted of open 
flap debridement and modified widman flap, the papilla preservation flap, the MPPT and 
SPPF, and finally the M-MIST.  The authors concluded that clinical performance may 
vary according to the type of flap used with the most conservative approach having the 
greatest CAL gain, probing depth reduction, and a decrease in recession.     
2.3.4 Minimally Invasive Surgery and Patient-Centered Outcomes 
 
 Studies have reported on the clinically significant outcomes of minimally invasive 
surgical approaches.  Furthermore, some of these studies have published patient-centered 
outcomes, which suggest a less traumatic patient experience when more minimally 
invasive approaches are used.  Several studies have reported the postoperative pain at one 
week, the pain intensity as measured by a visual analogic scale (VAS), and the number of 
analgesics consumed [33, 61, 74-76].  Cortellini et al. 2001 used SPPF/MPPT + 
bioresorbable barriers, Tonetti et al. 2004 used SPPF/MPPT + Emdogain; Cortellini et al. 
2007 used MIST + Emdogain; and Cortellini et al. 2011 used M-MIST + Emdogain. The 
outcomes for subjects with postoperative pain at 1 week in the aforementioned order 
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were 46%, 50%, 30% and 0%.  The pain intensity measurements were 28.1±2.5, 28±20, 
19±10, and “not measured.”  Lastly, the numbers of analgesics consumed were 4.1±2.5, 
4.3±4.5, 1.1±2, and 0.3±0.6.  This comparison of studies suggests a less traumatic 
surgical experience from the perspective of the patient, but no study has directly 
compared the double flap approach to the single flap approach.   
2.3.5 Double Flap Approach (DFA) and Single Flap Approach (SFA) with and without 
Grafting for Intrabony Defects: Clinical Studies 
 
 There are several clinical studies evaluating the use of the DFA and SFA with and 
without grafting.  The studies vary in the quality of evidence in that some are 
retrospective and others are prospective, randomized controlled clinical trials, but they 
are consistently showing remarkable clinical outcomes using these flap designs.   
 There are a group of studies where the DFA was used in the form of MIS 
(minimally invasive surgery) or MIST (minimally invasive surgical technique), and all 
results can be seen in Table 1.  In the DFA flap design, the entire papilla is elevated [33]. 
The outcomes from these seven studies show clinically significant levels of CAL gain 
and minimal changes in recession when MIS and MIST were used. In another group of 
studies, the Single Flap Approach (SFA) was used with treatment adjuncts, and in this 
surgical approach only one side of the interdental defect was accessed keeping the 
interdental papilla mostly intact.  The results can be seen in Table 2. The four SFA 
studies consistently show excellent CAL gains with minimal amounts of recession, which 
are comparable and often superior to the outcomes seen in the literature for the DFA.   
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There are only two studies in the literature that include the DFA and SFA in the 
same clinical trial.  The first study is a prospective study by Cosyn et al. where 95 
patients were treated with either MIST or M-MIST and grafted with a collagen-enriched 
bovine-derived xenograft [77]. After 1-year of healing, the CAL gain was 3.1 and the 
change in recession was 0.5 mm. This study demonstrated that using MIS and collagen-
enriched bovine-derived xenograft had favorable clinical outcomes in CAL gain and 
change in recession, and it also identified risk factors for failure.  In the second study, 
Trombelli et al. conducted a Randomized Controlled Trial (RCT) to compare the SFA to 
the DFA in treating 28 patients with 28 intrabony defects without treatment adjuncts [9].  
After six months of healing, the CAL gains for the SFA versus the DFA were 4.5 ± 1.1 
and 3.4 ± 1.4 mm, respectively, and this was a statistically significant greater CAL gain 
for the SFA.  For the change in recession, the SFA had 0.7 ± 0.8 mm and the DFA had 
0.5 ± 1.1 mm, and there was no statistically significant difference.   
 The literature reports excellent clinical results using minimally invasive surgeries 
either as a double flap approach or a single flap approach.  Moreover, the volume of 
evidence concludes that using these surgical approaches with treatment adjuncts also 
results in remarkable clinical outcomes, while it also suggests in some studies that the 
outcomes may be similar to the control groups where treatment adjuncts were not used.  
To date, there is only one randomized clinical trial directly comparing the SFA to the 
DFA.  It is well established that currently available regenerative grafts and biologics may 
lead to a true regeneration of the periodontal tissues lost to periodontitis [78-81].  What is 
not known is whether a surgical approach like the SFA, which maintains space for clot 
maturation and enhances wound stability, will potentiate the regenerative efficacy of a 
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regenerative material for a greater clinical benefit in comparison to another approach like 
the DFA.   
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TABLE 1.  Clinical studies where the double flap approach was used in conjunction with grafting and/or biologics 
 
MIS/MIST Type of study Interventions # of 
patients 
# of 
Defects 
CAL gain ∆ Recession 
Harrel et al 1999 [82] Retrospective MIS+DFDBA 87 194 4.87±0.27 Not reported 
Harrel et al 2005 [60] Case cohort MIS+EMD+DFDBA 16 160 3.57±1.75 0.01 
Cortellini et al 2007 [61] Case cohort MIST+EMD 13 13 4.8±1.9 0.1±0.9 
Cortellini et al 2007 [62] Case cohort MIST+EMD 40 40 4.9±1.7 0.4±0.7 
Cortellini et al 2008 [83] Case cohort MIST+EMD 20 44 4.4±1.4 0.2±0.6 
Ribeiro et al 2011 [84] RCT MIST 
MIST+EMD
 
15 
14 
15 
14 
2.82±1.19* 
3.02±1.94* 
0.54±0.58* 
0.46±0.87* 
Ribeiro et a 2011 [85] RCT MIST 
MINST 
14 
13 
14 
13 
2.85±1.19* 
2.56±1.12* 
0.48±0.51* 
0.45±0.46* 
 
EMD, enamel matrix derivative; MIS, minimally invasive surgery; MIST, minimally invasive surgical technique; MINST, minimally invasive nonsurgical 
technique; DFDBA, Decalcified Freeze Dried Bone Allograft 
*No statistical difference 
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TABLE 2. Clinical studies where the single flap approach was used in conjunction with grafting and/or biologic 
 
SFA/M-MIST Type of study Interventions # of 
patients 
# of 
Defects 
CAL gain ∆ Recession 
Cortellini et al 2009 [65] Case cohort M-MIST+EMD 15 15 4.5±1.4 0.07±0.3 
Cortellini et al 2011 [74] RCT M-MIST 
M-MIST+EMD 
M-MIST+EMD+BioOss 
15 
15 
15 
15 
15 
15 
4.1±1.4* 
4.1±1.2* 
3.7±1.3* 
0.3±0.6* 
0.3±0.5* 
0.3±0.7* 
Trombelli et al 2010 [68] RCT SFA 
SFA+HA+GTR 
12 
12 
12 
12 
4.4±1.5* 
4.7±2.5* 
0.8±0.8* 
0.4±1.4* 
Mishra et al. 2013 [86] RCT M-MIST 
M-MIST+rhPDGF-BB 
12 
12 
12 
12 
2.64±0.67* 
3.00±0.89* 
0.55±0.52* 
0.82±0.60* 
 
EMD, enamel matrix derivative; M-MIST, modified minimally invasive surgical technique; BioOss®; SFA, single flap approach; HA, hydroxyapatite, GTR, 
guided tissue regeneration; rhPDGF-BB, recombinant human platelet derived growth factor BB 
*No statistical difference 
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2.4 GEM-21 (rhPDGF-BB and β-Tricalcium Phosphate) 
 
 GEM-21 has been released as a promising therapeutic for periodontal 
regeneration of intrabony defects.  The active component is recombinant human platelet-
derived growth factor-BB and the carrier is β-Tricalcium Phosphate.   
2.4.1 An Introduction to Polypeptide Growth Factors and PDGF-BB 
 
 Polypeptide growth factors, such as platelet derived growth factor (PDGF), are 
hormone-like substances that bind cell membranes receptors, trigger intracellular 
signaling pathways, and activate genes causing an alteration in cell activity [87, 88].  The 
major source of PDGF in the body is the α-granules of the platelets.  PDGF is generally 
not detectable in the blood because it is rapidly cleared by PDGF-binding protein making 
its presence highly localized [89].  This important mechanism keeps distal tissues from 
inadvertently being exposed to the growth factor.  PDGF is expressed as different 
isomers: AA, AB, BB, CC, DD.  There are also two receptors, α and β, that bind to 
PDGF.  Periodontal tissues specifically express β-receptors, and β-receptors have the 
highest affinity for the BB isomer of PDGF[90].  Consequentially, GEM-21 uses 
rhPDGF-BB isomer.  
2.4.2 Mechanism of Action of rhPDGF-BB on Cells (in vitro studies) 
 
 Growth factors have been developed to enhance the regenerative potential of the 
periodontium.  In particular, rhPDGF-BB has been combined with bone substitutes in 
vitro to show promising effects on cells of the periodontium.  For example, in two studies 
human allografts were enriched with rhPDGF-BB to show positive effects on osteoblasts 
and periodontal ligament cells [91, 92].  In addition, Vavouraki et al. showed bovine bone 
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grafts with PDGF-BB stimulated PDL cells, and Bateman et al. showed two alloplastic 
bone matrices with PDGF-BB positively effected osteoblastic proliferation [93, 94].  
There are several studies that have identified the mechanisms of action that rhPDGF-BB 
exerts on the cells of the periodontium. 
 Platelet-derived growth factor has been shown to have various effects on 
periodontal ligament cells (PDL cells).  Nishimura et al. showed that PDGF induced a 
migratory response in a dose-dependent manner on PDL cells showing that PDGF had a 
chemotactic effect on PDL cells [95]. Two studies tested the effect of PDGF on PDL cell 
mitogenesis showing that PDGF had a mitogenic effect [96, 97].  Two studies 
investigated the effect of PDGF on matrix synthesis by PDL cells and their mitogenesis 
[98] [97].  PDGF was strongly mitogenic, and it also increased the production of matrix 
synthesis seen by an increase in proteoglycans measured (versican, biglycan, decorin). 
Lastly, Zaman et al. studied the effect of PDGF on the presence and attachment of human 
PDL cells to EDTA-demineralized dentin [99].  They showed that PDGF increased PDL 
cell attachment to the root, which is a prerequisite for periodontal ligament formation.  
These in vitro studies show that PDGF has a profound effect on PDL cell chemotaxis, 
mitogenesis, matrix synthesis, and PDL cell attachment to the root surface.   
There are in vitro studies that also show an effect of PDGF on the other cells of 
the periodontium: osteoblasts and cementoblasts.  In a study by Bateman et al., two 
alloplastic bone matrices enriched with PDGF-BB had a greater mitogenic effect on 
osteoblasts [93]. In another study, Park et al. showed that PDGF increased osteoblast 
mitogenesis and chemotaxis [100]. In regards to the effect of PDGF on cementoblasts, 
studies have investigated the effect of PDGF on cementoblasts in vitro and ex vivo [101, 
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102]. When PDGF was used, the results showed an increased mitogenic activity, and a 
level of biomineralization with greater incorporated neovascularization.  The results of 
this series of studies showed that PDGF increases mitogenesis and chemotaxis of 
osteoblasts, and that it increases mitogenesis in cementoblasts while increasing 
neovascularized biomineralization.   
2.4.3 The Use of β-Tricalcium Phosphate (β-TCP) 
 
 In vitro studies have elucidated the various effects that PDGF exerts on the cells 
of the periodontium by specifically showing the mechanisms through which it potentiates 
periodontal regeneration.  Choosing the proper carrier for the growth factor depended on 
the performance of the bone substitute in experimental studies.   
 In two experiments by Stahl and Froum, the healing of intrabony defects grafted 
with β-TCP was evaluated with human histology after eight and eighteen months.  At 
eight months, the β-TCP was shown to be a non-irritating filler, there was no 
inflammatory infiltrate, but the material did provide a scaffold for ingrowth of fibroblasts 
and showed encapsulation by connective tissue [103].  By eighteen months, particles 
remaining were surrounded by connective tissue without induction of inflammation, and 
it was almost fully resorbed [104].    
 In another study by Bateman et al., β-TCP enriched with PDGF was evaluated in 
vitro and in vivo in a mouse model, and the release of PDGF by the graft was measured 
[93].  The study showed after ten days, 45% had been released showing a slow, 
incremental release.  Besides these studies, several animal and human studies have 
demonstrated the biocompatibility of the β-TCP with no reports of adverse reactions 
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[105]. β-TCP has been shown to be not only biocompatible, but also an effective carrier 
for PDGF.  Also, after 18 months it has been shown to resorb almost completely without 
the presence of inflammation.  The product GEM-21 was developed using β-TCP and 
rhPDGF-BB for the treatment of human intrabony defects.   
2.4.4 Animal and Human Studies using rhPDGF-BB and β-TCP 
 
 PDGF has been topically applied to periodontally diseased root surfaces in beagle 
dogs, and substantial amounts of new bone, cementum, and periodontal ligament were 
present after two weeks [105-107].  These results were confirmed in three other studies 
using beagle dogs and also nonhuman primates [108-110].  The promising results from 
these animal studies lead to experimental case series in humans where rhPDGF-BB was 
used with bone allograft to treat Class II furcations and intrabony defects, and the clinical, 
radiographic, and histologic results were excellent [111-114].   
 These results prompted the organization of the multicenter randomized controlled 
trial where the safety and effectiveness of rhPDGF-BB and β-TCP was tested on 
intrabony defects in humans[4]. The results after six months of healing showed that β-
TCP/0.3mg/ml of rhPDGF-BB had the greatest clinical benefit.  In comparison to the β-
TCP/Buffer control, β-TCP/0.3mg/ml of rhPDGF-BB had a statistically significant 
difference for linear bone gain and percent bone fill, but no difference for CAL gain.  
Moreover, there were no adverse events reported, and the authors concluded that the 
regenerative material was safe and showed a clinical benefit at six months.  
 In another study, McGuire et al. showed human histology for the use of rhPDGF-
BB and β-TCP (GEM-21) [3]. All the sites treated with rhPDGF-BB and β-TCP (GEM-
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21) had evidence of regeneration defined by reformation of cementum, supporting 
alveolar bone, and a periodontal ligament with inserting connective tissue fibers. The 
authors concluded regeneration of the periodontium was possible with rhPDGF-BB and 
β-TCP (GEM-21).   
 A more recent multi-center randomized clinical trial evaluated the safety and 
efficacy of a formulation containing rhPDGF-BB with β-TCP versus β-TCP alone in 
patients with intrabony defects [2].  All three measurements were statistically significant 
in favor of the rhPDGF-BB with β-TCP test group.  The authors concluded that the 
treatment was safe because there were no adverse events reported, and that there was a 
clinically and statistically significant greater benefit using rhPDGF-BB with β-TCP.   
2.4.5 Systematic Reviews: rhPDGF-BB and β-TCP 
 
 Two systematic reviews evaluated the clinical benefit of using rhPDGF-BB with 
β-TCP for treating human intrabony defects.  Trombelli et al. found rhPDGF-BB in 
combination with a graft material showed beneficial effects in intrabony and furcation 
defects [6].  When rhPDGF-BB was used with allogenic bone grafts, substantial CAL 
gain and probing depth reduction were seen in case reports. One randomized clinical trial 
showed the efficacy of rhPDGF-BB with β-TCP for linear bone growth and percent 
defect fill.  It was concluded that further studies are needed to determine to what extent 
rhPDGF-BB with graft may be effective for periodontal reconstructive procedures.  
 A more recent systematic review and meta-analysis evaluated the use of rhPDGF-
BB with β-TCP for treating human intrabony defects [5].  A review of the literature 
resulted in two randomized clinical trials that qualified for a meta-analysis where 
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rhPDGF-BB with β-TCP (test) versus β-TCP alone (control) was used.  For CAL gain at 
3 months, the weighted mean difference in favor of the test group was 0.55 with a 95% 
CI [0.13, 0.96].  For CAL gain at 6 months, the weighted mean difference in favor of the 
test group was 0.62 with a 95% CI [0.23, 1.00].  For linear bone growth, the weighted 
mean difference in favor of the test group was 1.44 with a 95% CI [1.08, 1.80].  For 
percent bone fill, the weighted mean difference in favor of the test group was 24.87 with 
a 95% CI [15.40, 34.34].  The authors concluded within the limits of this systematic 
review and meta-analysis it appears that rhPDGF-BB with β-TCP has a greater clinical 
benefit than β-TCP alone, but more studies are needed to confirm this result.   
 In vitro studies have elucidated the various effects that PDGF exerts on the cells 
of the periodontium by specifically showing the mechanisms through which it potentiates 
periodontal regeneration.  The clinical efficacy of rhPDGF-BB with β-TCP in treating 
human intrabony defects is promising in the small amount of studies published to date.  
More randomized clinical trials are needed to confirm these results.  
2.5 Concluding Remarks on the Literature 
 
Decades of research in periodontal regeneration have produced various materials 
and products as well as innovative surgical approaches resulting in clinically significant 
levels of regenerative success for patients.  The success of regenerative therapy has been 
extensively reported and results have been shown to be stable over time in longitudinal 
clinical trials. Along with research into regenerative materials, a significant volume of 
research has investigated the innate regenerative potential of the periodontium.  Progress 
in flap management has moved towards smaller, less traumatic surgical approaches with 
 26
the goal of maximizing the innate healing potential of the periodontium.  The success of 
minimally invasive surgery has been confirmed in systematic reviews and meta-analyses, 
but to what extent one approach may have greater clinical benefit than another needs to 
be further investigated.  To date, there is only one randomized clinical trial directly 
comparing the single flap approach (SFA) to the double flap approach (DFA), whereas, 
these approaches have been tested extensively in the literature with other treatment 
adjuncts.  One recent regenerative material showing promise is GEM-21 (rhPDGF-BB 
with β-TCP).  In vitro studies have elucidated the mechanisms through which it 
potentiates periodontal regeneration by acting on the cells of the periodontium, and 
randomized clinical trials and systematic reviews have confirmed its clinical and 
statistical benefit in treating intrabony defects.  What is not known is whether a surgical 
approach like the SFA, which maintains space for clot maturation and enhances wound 
stability, will potentiate the regenerative efficacy of a treatment adjunct like GEM-21 for 
a greater clinical benefit in comparison to another surgical approach like the DFA.  
Moreover, will there be a more favorable patient-centered outcome with the more 
minimally invasive SFA?  
3. Aim, Hypothesis, and Objectives 
 
3.1 Aim 
 
To compare the clinical, radiographic, and patient-centered outcomes of a 
regenerative strategy based on the use of rhPDGF-BB + β-TCP in deep intraosseous 
periodontal defects accessed with SFA versus DFA. 
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3.2 Hypothesis 
 
The treatment of intraosseous periodontal defects with single flap approach + 
rhPDGF-BB/β-TCP will improve clinical, radiographic, and patient-centered outcomes 
when compared with the use of a double flap approach + rhPDGF-BB/β-TCP. 
3.3 Objectives 
 
3.3.1 Primary Objectives 
 
 To evaluate the clinical outcome (CAL, PD, Recession (REC)) after treatment of 
intraosseous periodontal defects with SFA+ rhPDGF-BB/β-TCP versus DFA+ rhPDGF-
BB/β-TCP. 
 To evaluate patient perception of pain and discomfort between SFA+ rhPDGF-
BB/β-TCP versus DFA+ rhPDGF-BB/β-TCP. 
3.3.2 Secondary Objectives 
 
To evaluate radiographic bone changes after treatment of intraosseous periodontal 
defects with SFA+ rhPDGF-BB/β-TCP versus DFA rhPDGF-BB/β-TCP. 
 To evaluate the quality of wound closure after using SFA+ rhPDGF-BB/β-TCP 
versus DFA+ rhPDGF-BB/β-TCP.  
4. Study Design and Procedures 
 
4.1 Study Design 
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The study was a randomized, controlled parallel-arm trial. Patients were recruited 
at the Division of Periodontology, School of Dental Medicine, University of Connecticut 
(Farmington, CT). Each patient contributed one intraosseous periodontal defect to the 
trial. All intraosseous defects were grafted with rhPDGF-BB (0.3 mg/ml) + β-TCP. The 
clinical procedures differed between groups for the soft tissue management (SFA or 
DFA) only. Flow chart and visit schema are reported in Figure 1.  For Visit 6 the clinical 
parameters included clinical attachment level (CAL), probing depth (PD), recession 
(REC), bleeding index (BI), plaque index (PI), and bleeding sites (BS).  For Visit 11, the 
clinical parameters included CAL, PD, REC, and BS.   
  
Figure 1: Flow chart and visit schema. 
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4.2 Screening Procedures 
 
 The subjects for the investigation were recruited among patients diagnosed with 
chronic or aggressive periodontitis in the post-graduate periodontology clinic at 
University of Connecticut Health Center. An initial evaluation was conducted to 
determine whether a patient met the study inclusion criteria. This evaluation included 
medical history, clinical examination, and radiographic examination (from existing full 
mouth x-ray or orthopantomograms).  
Inclusion and exclusion criteria are summarized in Table 3. 
 
Table 3: Inclusion and exclusion criteria. 
Inclusion Criteria Exclusion Criteria 
• Males and females at least ≥ 18 
years of age 
• Provision of informed consent 
• Diagnosis of chronic or aggressive 
periodontitis 
• Presence of at least one deep 
(probing depth ≥ 6mm, 
radiographic depth of ≥ 3mm) 
interproximal intraosseous 
periodontal defect; limited to no 
extension of the defect on the 
lingual/palatal side as assessed by 
Conditions that prevented study 
participation: 
• Time constrain that prevented 
returning to follow up visit 
• Inability to follow investigator’s 
instruction 
• No compliance with the study 
requirements 
• Simultaneous participation in other 
studies 
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bone sounding 
• Full Mouth Plaque Score [115] and 
Full Mouth Bleeding Score < 20% 
at the time of the surgical procedure 
• Third molars will be excluded 
Systemic conditions: 
• Conditions requiring chronic 
routine use of antibiotics or 
requiring prolonged use of steroids 
• Long-term use of bisphosphonate (≥ 
3 years) 
• History of leukocyte dysfunction or 
deficiencies, bleeding disorders, 
neoplastic disease requiring 
radiation or chemotherapy, 
metabolic bone disorder, 
uncontrolled endocrine disorders, 
HIV infection 
• Use of investigational drugs or 
devices within 30 days of study 
period 
• Alcoholism or drug abuse 
• Smoking >10 cigarettes per day 
Local conditions (experimental tooth): 
• Inadequate restoration 
• Endodontic lesions 
• Inadequate endodontic treatment 
• Active carious lesion 
 
 
4.3 Pre-surgical Procedures 
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Each patient had a full-mouth session of scaling and root planing (SRP) using 
mechanical and hand instrumentation, and they received personalized oral hygiene 
instructions. The surgical phase was delayed until the patient achieved a minimal residual 
inflammation and optimal soft tissue conditions at the defect site. Up to four sessions of 
SRP were considered to achieve this goal. Patients were excluded from the trial if after 
this period the plaque index and bleeding index were higher than 20%.  
4.4 Allocation and Allocation Concealment 
 
Every patient was given a subject identification number. An independent 
investigator, not involved with patient treatment, generated the allocation list. Computer 
software was used to randomize the subject identification numbers into one of the two 
groups. This information was concealed in sealed envelopes, which were opened before 
the surgical treatment. Neither the surgeon, nor the patient was aware of the group 
assignment until the day of surgery.  
In addition, a calibrated examiner masked with respect to treatment allocation 
performed the clinical measurements. 
4.5 Surgical Procedures 
 
The same experienced operator performed all surgeries using 4.0 magnifying 
loops. The site of surgery was anesthetized using Lidocaine-epinephrine 1:100,000. 
Transcrevicular probing (bone sounding) was performed pre-surgery to determine the 
characteristics of the bony defect, such as the defect morphology and extension, the 
probing bone level, and the horizontal component of bone loss.  Defects with an 
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extension past the line angles determined by bone sounding were treated with the DFA 
but excluded from the study.  
4.5.1 Single Flap Approach Group 
 
In the SFA group, the surgical access was performed by the elevation of either a 
buccal or lingual mucoperiosteal flap according to previously detailed principles [35, 63, 
64]. Briefly, a buccal or lingual envelope flap without vertical releasing incisions was 
performed. Sulcular incisions were made following the gingival margin of the teeth 
included in the surgical area. The mesio-distal extension of the flap was kept limited 
while ensuring access for defect debridement. An oblique or horizontal, butt-joint 
incision was made at the level of the interdental papilla overlying the intraosseous defect. 
The greater the distance from the tip of the papilla to the underlying bone crest, the more 
apical (i.e., close to the base of the papilla) the buccal or lingual incision in the 
interdental area. However, the interdental incision was placed at least 1 mm coronal to 
the underlying bone crest. This provided an adequate amount of supracrestal soft tissue 
connected to the undetached papilla to ensure subsequent flap adaptation and suturing, 
and it permitted proper surgical access to the defect. For each defect, a microsurgical 
periosteal elevator was used to raise a flap only on the buccal or lingual side, leaving the 
other portion of the interdental supracrestal soft tissues undetached. Root and defect 
debridement were performed using Minifive™(Hu-Friedy) curettes and ultrasonic 
instruments. After surgical debridement, defects were grafted with rhPDGF-BB + β-TCP 
(GEM 21S®; BioMimetic Therapeutics, Franklin, TN). β-TCP was mixed with rhPDGF-
BB (0.3 mg/ml) and allowed to sit for  10 minutes to permit binding of the rhPDGF-BB 
protein to the β-TCP before being placed into the defect. For wound closure, a horizontal 
 33
internal mattress suture (Monosoft 6.0 Covidien Mansfield MA, USA) was placed 
between the flap and the base of the attached papilla to ensure repositioning of flap. A 
second internal mattress suture (vertical or horizontal) was placed between the most 
coronal portion of the flap and the most coronal portion of the papilla as needed. See 
Figure 2 for an illustration of the technique. 
       
Figure 2: Surgical steps for the Single Flap Approach. 
4.5.2 Double Flap Approach Group 
 
In the DFA group an envelope flap without vertical releasing incisions was 
performed at both buccal and lingual aspects. Sulcular incisions were placed following 
the gingival margin of the teeth included in the surgical area. The defect-associated 
interdental tissue was approached with surgical techniques for the preservation of the 
interdental papilla, namely the simplified papilla preservation flap (SPPF)  [57] or the 
modified papilla preservation technique (MPPT) [56]. The selection of the flap design 
depended on the operator’s evaluation [116]. The mesio-distal extension of the flaps was 
minimized while maintaining an adequate surgical access for a proper root and defect 
debridement. Partial-thickness dissection was limited to the apical portion of the buccal 
flap to obtain the desired flap mobilization and ensure tension-free suturing. Root and 
 34
defect debridement were performed using hand and ultrasonic instruments. After surgical 
debridement, defects were grafted with rhPDGF-BB + β-TCP (GEM 21S®; BioMimetic 
Therapeutics, Franklin, TN). The material was prepared as previously described. When 
MPPT was applied, the flaps were sutured using horizontal and vertical internal mattress 
(or interrupted) sutures [56]. A horizontal internal mattress suture was placed between the 
base of the lingual flap and the buccal flap coronal to the mucogingival junction in order 
to coronally displace the buccal flap. Then, a vertical internal mattress suture (or an 
interrupted suture) was placed between the most coronal portion of the lingual flap, 
which included the interdental papilla, and the most coronal portion of the buccal flap. 
See Figure 4 for an illustration of the MPPT.  When the SPPF was applied, primary 
closure was achieved as previously described [57]. First, a horizontal internal mattress 
suture was placed in the defect-associated interdental space, from the base of the gingiva 
(close to the mucogingival junction) at the mid-buccal aspect of the tooth not involved by 
the defect to a corresponding location at the base of the lingual flap. This suture rested on 
top of the highest peak of the interdental bone crest and was anchored to the lingual flap. 
This “offset” suture allowed for tension-free coronal positioning of the buccal flap by 
rubbing against the root surface and lying on top of the residual bone crest. The 
interdental tissue above the defect was then closed with one or two interrupted sutures or 
an internal vertical mattress suture (as in MPPT), depending on the width of the 
interdental space and the thickness of the interdental tissue [57]. See Figure 3 for an 
illustration of the SPPF.  In all cases a non-resorbable monofilament suture (Monosoft 
6.0 Covidien Mansfield MA, USA) was used. 
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Figure 3: Surgical steps for the Double Flap Approach, specifically the Simplified 
Papilla Preservation Flap (SPPF). 
     
Figure 4: Surgical steps for the Double Flap Approach, specifically the Modified Papilla 
Preservation Technique (MPPT).  
 
4.6 Post-surgery Procedures 
At the end of each session, patients were prescribed a rescue analgesic (Ibuprofen 
600 mg) to control post-treatment pain and discomfort. Sutures were removed at 2 weeks 
post-surgery. The patients were asked to abstain from mechanical oral hygiene 
procedures in the surgical area for 4 weeks. A 0.12% Chlorhexidine mouthrinse (10 mL 
BID/2 wks) was used to support local plaque control. Each patient was inserted in a 
monthly recall program for 3 months and was reviewed according to personal needs 
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thereafter. Each session included reinforcement of oral hygiene procedures and 
supragingival plaque removal. Subgingival scaling was performed following completion 
of the study at 6 months post-surgery. 
4.7 Sample Size and Power Analysis 
 
The sample size was calculated assuming a standard deviation of CAL change of 
1.5 mm. A minimum sample size of 24 patients (12/group) was needed to detect a 
difference in CAL change of 1.5 mm between groups, using a parametric test with a 0.05 
two-sided significance level at a statistical power of 87%.   
5. Data Collection 
 
5.1 Training and Calibration 
 
Before the study initiation, a calibration session was performed to evaluate (i) the 
intra-examiner agreement in the assessment of clinical recordings and (ii) the intra- and 
inter-examiner agreement in the assessment of radiographic measurements. 
5.2 Clinical Records 
 
 Calibrated masked examiners performed all clinical recordings. The following 
parameters were recorded on the treated tooth and the two adjacent teeth if applicable.  
This was done immediately pre-surgery and at the completion of study at 6 months using 
a manual pressure sensitive probe (UNC 15, Hu-Friedy, Chicago, IL, USA) with 1-mm 
increments and using approximately 0.3-N force. Measurements were rounded off to the 
nearest mm. 
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• Probing depth (PD), measured from the gingival margin to the bottom of the 
pocket; 
• Clinical attachment level (CAL), measured from the cemento-enamel junction 
(CEJ) to the bottom of the pocket; 
• Gingival recession (REC), measured from the CEJ to the gingival margin; 
• Local bleeding score (BS): recorded as positive when bleeding on probing was 
present at the surgical site. 
PD, CAL and REC were recorded at six aspects per tooth: mesio-buccal, mid-buccal, 
disto-buccal, mesio-lingual, mid-lingual, and disto-lingual.  
5.3 Full Mouth Bleeding Score 
 
Four sites per tooth were evaluated for bleeding on probing. The total number of 
positive sites was divided by the total number of sites and presented as a percentage. A 
score of ≤ 20% was needed to proceed to the surgical phase. 
5.4 Full Mouth Plaque Index 
 
Four sites per tooth were evaluated for the presence or absence of dental plaque. 
The number of positive sites was divided by the total number of sites and presented as 
percentage. A score of ≤ 20% was needed to proceed to the surgical phase. 
5.5 Intra-surgical Measurements 
 
At the completion of the intra-surgical debridement, the distance between the CEJ 
and the base of the defect as well as the depth of the intrabony component (measured as 
the distance between the deepest point of the defect and the most coronal point of the 
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alveolar crest at the adjacent tooth) were assessed. In addition, the configuration of the 
defect with respect to the number of bony walls was also recorded. 
5.6 Early Wound-healing Index 
 
 At suture removal, 2 weeks post-surgery, any complications were recorded. 
Wound closure was evaluated using the early wound-healing index [117]: 
1 - complete flap closure – no fibrin line in the inter-proximal area; 
2 - complete flap closure – fine fibrin line in the inter-proximal area; 
3 - complete flap closure – fibrin clot in the inter-proximal area; 
4 - incomplete flap closure – partial necrosis of the inter-proximal tissue; 
5 - incomplete flap closure – complete necrosis of the interproximal tissue. 
5.7 Radiographic Measurements 
 
 Standardized radiographs were obtained immediately before surgery as well as at 6 
months after surgery using a bite plane indexed with composite material. The clinical 
examiner assessed the quality of the films prior to the release of the patient to ensure 
diagnostic quality. Radiographs were sent to a blinded operator. The films were digitized, 
and linear radiographic measurements were analyzed for bone changes. The following 
linear measurements were taken on the pre-surgery and 6-month digitized periapical 
radiographic images: 
• Distance (in mm) between the CEJ and the most apical extension of the defect 
(i.e., where the periodontal ligament space is considered having a normal width); 
• Distance (in mm) between the CEJ and the bone crest of the adjacent tooth; 
• Distance (in mm) between the CEJ and the root apex. 
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For each digitized radiograph, linear bone growth (LBG) was calculated as CEJ to base 
of the defect at baseline minus CEJ to base of the defect at 6 months. Also, percent bone 
fill was calculated by dividing LBG by the depth of the original bone defect. 
 All radiographs to date have been sent to the blinded examiner who will complete 
the measurements once all the patients have finished the study.  These measurements will 
not be available for the purpose of the present thesis. 
5.8 Patient Perception of Pain 
 
 A visual analog scale (VAS, 100 mm) was used to assess the subject’s self-
perceived pain (VAS). Assessments were performed immediately after surgery, at 8 a.m., 
1 p.m. and 8 p.m. on the 1st, 2nd and 3rd postoperative day, and at 8 p.m. on the 4th, 5th and 
6th, 7th and 14th postoperative day.  
 For the use of self-administered anti-inflammatory drugs/analgesics, the patients 
were asked to record any postoperative consumption (timing, dosage) of the rescue 
analgesic.  
5.9 Method of Data Analysis 
 
Statistical software (SPSS v.18; Chicago, IL) was used for data analysis. The 
patient was regarded as the statistical unit. The aspect of the tooth topographically related 
to the intraosseous defect presenting the largest CAL value pre-surgery was used for 
comparisons and statistical analysis of outcome variables. Data were expressed as mean ± 
standard deviation (SD). 
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The Kolmogorov-Smirnov’s test was used to assess the normal distribution of 
each parameter. Intra-group comparisons were performed with the Paired t test and the 
Wilcoxon signed-rank test for parametric and non-parametric variables, respectively. 
Inter-group comparisons were performed with the Independent t test and the Mann 
Whitney rank-sum test for parametric and non-parametric variables, respectively.  For 
nominal and ordinal data the Chi-square test and Mann-Whitney rank-sum test were used, 
respectively. The level of significance was set at 5% for all statistical tests.   
6. Results 
 
6.1 Study Population  
 
The patient flow and allocation during the study are reported in Figure 5.  
A total of 29 patients were treated.  All patient healing was uneventful.  One patient was 
excluded from the statistical analysis because of an endodontic complication detected at 
visit 11.  As per intent to treat, the data relative to this participant until Visit 11 were 
included in the analysis.  In the present interim report we are presenting data relative to 
22 patients completed.  Six patients are still in the recall stage.  For the 22 patients who 
completed the study, the characteristics of the study population are summarized in Table 
4.  There was no significant difference between the groups for age (P=0.5 Independent T-
Test), smokers (P=1.0 Chi-squared Test), full mouth bleeding score (FMBS) (P=0.2 
Independent T-Test), and full mouth plaque score (FMPS) (P=0.4 Independent T-Test).  
Defect characteristics were summarized in Table 5.  There was no significant difference 
between the groups for depth of the intraosseous component of the defect (IBD) 
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(P=0.053 Independent T-Test).  None of the patients in the SFA group were excluded 
from the study because of an insufficient surgical access or an extension of the defect 
morphology preventing an adequate root and defect instrumentation.  All 22 patients who 
completed the study fully complied with the recall program.  All defects were reevaluated 
at 6-months post-surgically.  
 
Figure 5: Patient flow and allocation of the study 
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Table 4: Study Population 
Characteristic SFA (n = 12) DFA (n = 11) P 
Gender (M/F) 7/5 6/5  
Age (mean ± SD) 55.1 ± 13.8 48.0 ± 13.8 .5 
Smoker (yes/no) 2/10 0/10 1.0 
FMBS (mean ± SD) 8.0 ± 6.1 5.8 ± 5.9 .2 
FMPS (mean ± SD) 8.8 ± 6.0 6.4 ± 6.5 .4 
FMBS = Full Mouth Bleeding Score; FMPS = Full Mouth Plaque Score 
 
Table 5: Defect characteristics (mean ± SD) 
Characteristic SFA (n = 12) DFA (n = 11) P 
Dental Arch (n) 
 Maxillary 
 Mandibular 
 
6 
6 
 
5 
6 
 
Tooth type (n) 
 Incisor 
 Canine 
 Premolar 
 Molar 
 
3 
0 
5 
4 
 
2 
2 
3 
4 
 
IBD (mm) 7.1 ± 2.08 5.8 ± 1.69 .053 
IBD = intraosseous component of the defect 
 
6.2 Clinical Measurements 
 
 Baseline and 6-months values of the clinical parameters are reported in Table 6. 
Figures 6-8 compare SFA and DFA from baseline to 6-months. CAL significantly 
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decreased from baseline to 6-months with the SFA (P=0.002 Wilcoxon Signed Ranks 
Test) and the DFA (P=0.005 Wilcoxon Signed Ranks Test).  There was no significant 
difference between the groups (P=0.5 Independent T-Test).   
 PD significantly decreased from baseline to 6-months with the SFA (P=0.002 
Wilcoxon Signed Ranks Test) and the DFA (P=0.002 Wilcoxon Signed Ranks Test).  
The change from baseline to 6-months for the SFA and DFA were 4.1 ± 1.8 and 3.9 ± 1.0, 
respectively.  There was no significant difference between the groups (P=0.9 Mann-
Whitney Test). 
 There was no significant increase in REC from baseline to 6-months for the SFA 
(P=1.0 Wilcoxon Signed Ranks Test) or DFA (P=0.3 Wilcoxon Signed Ranks Test).  
The change from baseline to 6-months for the SFA and DFA were 0.0 ± .8 and -.3 ± 1.4, 
respectively. There was no significant difference between the groups (P=0.9 Mann-
Whitney Test). 
 There was no significant difference for Bleeding Sites (BS) between baseline and 
6-months for the SFA (P=0.08 Chi-squared Test) and DFA (P=1.0 Chi-squared Test) 
groups. 
 The Early Healing Index (EHI) summarized by type was reported for SFA and 
DFA in Table 7.  There was no significant difference between the groups (P=0.9 Mann-
Whitney Test).   
6.3 Patient-Centered Outcomes 
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 Average self-perceived pain VAS score and the total number of analgesic doses 
consumed are reported for SFA and DFA in Table 8.  There was a significant difference 
between the groups for average VAS score with the SFA groups reporting a lower level 
of pain (P=0.01 Mann-Whitney Test).  There was no significant difference between the 
groups for the total number of analgesic doses (P=0.09 Mann-Whitney Test).  
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Table 6: CAL (mean ± SD), PD (mean ± SD), REC (mean ± SD), BS (frequency). 
Parameter Baseline (mm) 6 Months (mm) P Change (mm) 
Baseline – 6 Months 
CAL 
 SFA 
 DFA 
 P 
 
9.6 ± 2.6 
8.3 ± 1.5 
 
5.2 ± 2.9 
4.9 ± 1.7 
 
.002 
.005 
 
4.3 ± 2.3 
3.7 ± 1.4 
.5 
PD 
 SFA 
 DFA 
 P 
 
8.4 ± 1.9 
7.9 ± 1.5 
 
 
4.1 ± 1.3 
4.0 ± 1.5 
 
.002 
.002 
 
4.1 ± 1.8 
3.9 ± 1.0 
.9 
REC 
 SFA 
 DFA 
 P 
 
1.2 ± 1.4 
.4 ± .8 
 
1.3 ± 1.7 
.9 ± 1.6 
 
1.0 
.3 
 
0.0 ± .8 
-.3 ± 1.4* 
.8 
BS (positive/negative) 
 SFA 
 DFA 
 P 
 
6/6 
8/3 
 
6/6 
2/8 
 
.08 
1.0 
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* Negative value for Recession represents an increase in recession. 
 
Table 7: Early Healing Index 
Early Healing 
Index (Type) 
SFA (n = 12) DFA (n = 11) P 
 1 
 2 
 3 
 4 
 5 
9 
1 
0 
2 
0 
7 
2 
1 
0 
1 
 
 Median 1.0 1.0 .9 
 
Table 8: Patient-centered outcomes. 
Parameter SFA DFA P 
VAS Score (mean ± SD) 2.1 ± 3.0 14.0 ± 17.8 .01 
Total # of Analgesic Doses 
(Mean ± SD) 
3.2 ± 5.9 9.6 ± 13.2 .09 
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Figure 6:  CAL from baseline to 6-months for SFA and DFA. 
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Figure 7:  PD from baseline to 6-months for SFA and DFA. 
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 Figure 8:  REC from baseline to 6-months for SFA and DFA.
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7. Discussion 
 
 The present study compares clinical and patient-centered outcomes of 
intraosseous periodontal defects accessed with either the SFA or DFA and grafted with 
rhPDGF-BB + β-TCP. For this interim report we present data from 12 patients treated 
with the SFA, and 10 patients treated with the DFA.  None of the patients were excluded 
due to inadequate access and debridement.  All the defects received a graft, and primary 
wound closure was achieved.   
The present study was based on the assumption that a minimally invasive 
approach like the SFA, which maintains space for clot maturation and enhances wound 
stability, would potentiate the regenerative outcome of a treatment adjunct like GEM-21 
for a greater clinical benefit in comparison to another surgical approach like the DFA.  
The analysis showed the SFA and DFA combined with rhPDGF-BB + β-TCP 
resulted in significant CAL gains and PD reductions at 6 months post-surgery compared 
to baseline, and they were similarly effective when compared for the change between 
baseline and 6-months.  These results are consistent with a previously published RCT 
using SFA vs. DFA without the use of any treatment adjuncts [9].  In a recent systematic 
review, Graziani et al. showed the greatest CAL gain when the SFA and the DFA were 
used in comparison to less conservative surgical approaches [7].  Moreover, the additions 
of treatment adjuncts like Demineralized Freezed Dried Bone Allograft (DFDBA) and 
EMD with the DFA [60-62, 82-84] as well as the use of EMD, BioOss, and HA/GTR 
with the SFA have resulted in significant CAL gains, which is consistent with the results 
of the present report [65, 68, 74]. It is well established that these conservative surgical 
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approaches when used alone or with treatment adjuncts have resulted in significantly 
improved clinical outcomes.  The regenerative material, GEM-21, has been shown in 
vitro to have various effects on PDL cells, osteoblasts, and cementoblasts such as 
enhancing mitogenesis and chemotaxis [93, 95-97, 100-102].  Furthermore, a recent 
systematic review and meta-analysis evaluated the use of rhPDGF-BB with β-TCP for 
treating human intrabony defects, and they showed significant CAL gain, linear bone 
growth and percent bone fill [7].  Both the present study and Trombelli et al. 2012 have 
exceeded the reported means for CAL gain reported by Graziani et al. 2012.  It can be 
speculated that the level of CAL gain achieved with these approaches may be due to 
smaller, less traumatic surgery that maximizes the innate healing potential of the 
periodontium by providing stability for the blood clot and wound, and also by achieving 
primary wound closure for blood clot protection. 
The minimally invasive approaches used in this study may have minimized the 
surgical trauma during the manipulation of the soft tissues resulting in no significant 
increase in REC from baseline to 6-months post-surgery for both the DFA and SFA.  
While intergroup comparisons showed no significant difference, there was a trend for a 
smaller increase in REC for the DFA compared to the SFA.  It should be considered that 
no difference between groups might be due to the small sample size of this interim report.  
The SFA maintains the interdental, supracrestal, gingival tissue intact, and it facilitates 
flap repositioning and suturing by utilizing the undetached papilla as anchorage; thus, 
optimizing wound closure for primary intention healing.  Moreover, limiting the surgical 
trauma on the papilla diminishes the vascular impairment that occurs as a result of trauma, 
which may partly explain a trend for minimal recession seen with the SFA.  This 
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speculation was supported by the results of Retzepi et al. that showed the conservative 
simplified papilla-preservation flap (SPPF) having a faster restoration of the normal 
perfusion of the gingival tissues compared to sites accessed with the less conservative 
modified Widman flap design [73].  The present study resulted in less post-surgical 
recession than the aforementioned study where SFA and DFA were used without 
treatment adjuncts [9].  This may suggest that by using rhPDGF-BB + β-TCP for space 
provision it provided support for the interdental, supracrestal tissue preventing tissue 
collapse, which otherwise would result in increased REC due to post-surgery tissue 
remodeling.  Trombelli et al. when comparing the SFA versus the SFA with 
GTR/Hydroxyapatite graft also observed this trend [68].  The grafted group had slightly 
less post-surgical REC although it was not significantly different.  
There was no significant difference between the SFA and DFA in the quality of 
early wound healing as both groups reported a median of Type 1 using the Early Wound 
Healing Index [117].  Type 1 is the best quality healing, and it is described as complete 
flap closure with no fibrin line in the inter-proximal area.  This can be partly due to the 
surgical design ensuring primary closure at the time of surgery for both approaches.  The 
SFA maintains the interdental, supracrestal, gingival tissue intact, and it facilitates flap 
repositioning and suturing by utilizing the undetached papilla as anchorage. The DFA 
mobilizes the flaps on both sides of the defect allowing for passive coronal displacement 
of the flaps for primary closure.  Minimal levels of dehiscence and better quality healing 
using the DFA (SPPF and MPPT) and the SFA have been reported in other studies [61, 
62, 64, 65].  In two studies, the SFA/M-MIST was compared to the SFA/M-MIST with 
treatment adjuncts, and the authors reported more incidences of poorer quality healing or 
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dehiscence in the grafted groups [68, 74].  This is contrary to the outcome observed in the 
present study, which may indicate that the minimally invasive surgical approaches used 
enhanced the regenerative potential GEM-21 allowing rhPDGF-BB to potentiate the 
speed and quality of healing.  Retzepi et al. showed a faster restoration of the normal 
perfusion of the gingival tissues when a more minimally invasive surgical approach is 
used, and vascularity is one determinant of the speed and quality of healing [73].  In 
addition, studies have shown that rhPDGF-BB upregulates angiogenesis by necessitating 
recruitment and differentiation of pericytes [118-120].  These are smooth muscle-like 
cells that regulate the morphology and function of vessels.   
Regarding the patient-centered outcomes, the SFA group reported a significantly 
lower level of pain than the DFA group as assessed by a VAS scale delineating self-
perceived pain.  While there was no significant difference between groups for the number 
of analgesic doses consumed, there was a trend for less consumption in the SFA group.  It 
should be considered that no difference between groups might be due to the small sample 
size of this interim report.  A review of the literature indicates several studies have 
reported the patient’s pain intensity as measured by a visual analogic scale (VAS), and 
the number of analgesics consumed when either a DFA or SFA were used [33, 61, 74-76]. 
A comparison of the studies shows a lower pain score and less consumption of analgesics 
when the SFA/M-MIST was used.  This was confirmed through a direct comparison 
between the SFA and DFA in the present RCT, and this suggests that the elevation of 
only a buccal or lingual flap rather than both is a less traumatic surgical experience from 
the perspective of the patient. 
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In the present study, only intraosseous defects limited to the interdental space and 
not extending past the line angles were selected.  This inclusion criterion created the 
proper clinical conditions for the application of the SFA.  As a result, the conclusions 
drawn from this study are only applicable in clinical situations reflecting the selection 
criteria suitable for the SFA.  Any lack of significance found in this interim report should 
be taken with caution, and these results need to be confirmed once all the data are 
collected for all subjects.   
8. Conclusion 
 
 The results of the study indicate that the surgical debridement of deep 
intraosseous periodontal defects using the SFA and DFA and then grafting with rhPDGF-
BB + β-TCP resulted in significant CAL gains, PD reductions, and no significant increase 
in REC.  Utilizing both of these treatment approaches resulted in a superior quality of 
healing at 2-weeks post-surgery.  Within the limitations of the study, it appears that the 
SFA with rhPDGF-BB + β-TCP results in excellent clinical outcomes while minimizing 
post-surgery morbidity from the perspective of the patient.   
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